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Clinical Trials Office (CTO) launched
Clinical trials research is
integral to Baystate Health’s
identity. It offers state-of-theart treatments to our patients
in western Massachusetts. It
enables Baystate Health to
collaborate with pharmaceutical
and device manufacturers that
are creating the next generation
of therapeutic interventions. In
addition, clinical trials research
promotes both the quality and
diversity of faculty through academic engagement, enhances
the recruitment and retention of
skilled professionals by creating
an atmosphere of scholarly
inquiry, and raises the local,
regional and national stature of
the institution.
According to clinicaltrials.
gov, a clinical trial, by definition,
“involves research using human
volunteers (participants) that
is intended to add to medical
knowledge. Participants receive
specific interventions (like drugs,
devices, or procedures) according to the research plan or protocol created by the investigators.” Such studies are essential
to advance evidence-based
medical practice. However,
the regulatory and operational
demands of clinical trials have
magnified in recent decades.
To meet these challenges, the
Office of Research launched the
new Baystate Health Clinical
Trials Office (CTO) in September
2018.
“Given the tremendous
expense of health care, all
sectors in our society have a
vested interest in finding better

Jay Steingrub, MD, Director of the Center for Clinical Trials and Translational
Investigation, and Lori-Ann Kozikowski, RN, BSN, CTO Program Director.

strategies of patient evaluation and treatment,” says Jay
Steingrub, MD, Director of
the new Clinical Trials Office.
“Such important efforts need
to encompass the biological
sciences, epidemiology, use
of new technologies and other
health care related resources.
Research is critical to the future
of health care; without supporting research we are left with a
myopic acceptance of the current therapeutic and diagnostic
limitations for our patients.”
BUILDING THE CLINICAL
TRIALS OFFICE
After over a year of planning,
the CTO has been set up to
provide new infrastructure for

clinical trials at Baystate Health.
The goal is to advance Baystate’s capabilities to participate
in industry-sponsored clinical
trials. The initial approach
is to concentrate on those
services most sought after by
industry and by our own faculty.
These include such elements
as a single point of contact,
improved contracting efficiency,
an up-to-date investigator
database, appropriate facilities
for company monitors, and
assistance with planning and
executing studies, including
nurse coordinator services.
“The CTO is expanding its
role to include the development
of patient recruitment services, training and educational

Research Question? Call the Office of Research at our central number: (413) 794-3391

programs for nurse coordinators
and research assistants and
physician investigators and
eventually the development of a
satellite site network at Baystate
Franklin Medical Center,” says
Steingrub. “Perhaps the most
unique aspiration for the CTO
is comprehensiveness. The
goal of the CTO is to provide
one-stop shopping in that all the
resources required for conducting a clinical trial at Baystate are
available within the CTO team.”
Everyday activities of the CTO
rely on coordinating the activities of the entire team within the
Office of Research, including
Sponsored Programs Administration and the Human Research
Protection Program. This
collaboration will make sponsor interactions with Baystate
efficient and effective. It will
also reduce the usual start up
barriers facing new investigators
who want to become involved in
the clinical trials process.
“More than anything else,
it’s the ease of working with
a group that is dedicated to
the same goals; that is timely,
accurate and reliable completion of important clinical trials,”
adds Steingrub. “This is our mission: for the CTO to support the
effective, efficient and reliable
evaluation of new pharmaceuticals, and medical devices in
collaboration with sponsoring
organizations, including industry
and government.”
Lori Kozikowski, RN, BSN,
CTO Program Director, shares
(Continued on page 2)
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(Continued from page 1)
this vision.
“All components of the CTO
will fall under one umbrella,”
she says. “The CTO continues
to grow and we are working
hard to make it less onerous to
start and operate clinical trials at
Baystate.” As Program Director,
Kozikowski is available to clinical trial and research personnel at Baystate to help with
compliance issues, quality, data
integrity, training and educating
new research staff, and stable
workforce planning. She is committed to providing the necessary tools and education to our
researchers.

THE FUTURE OF CLINICAL
TRIALS AT BAYSTATE
The Baystate CTO links to
researchers and patients at
other institutions and in other
communities as well.
“The CTO has created an
avenue for not only our external
subjects, but also for UMass
Amherst and UMass Worcester
scientists to better align with our
doctors and researchers here
at Baystate,” Steingrub adds.
“Through our research, many
of our discoveries are able
to be shared with the clinical
population.”
“It’s all about addressing the
needs of the population,” says
Kozikowski. “When people are

A Hello from the
[New] Editor
Hi everyone,
For those of
you who don’t
know me, my
name is Allison
Litera (most
people call me
Allie). I am the
Digital Content
Analyst for the
Offices of Faculty
Affairs and
Research here at
UMMS-Baystate.
I have been part
of the team since
October 2018 and am thrilled to be bringing
back The Innovator as the writer, editor, and
designer of this quarterly publication.
I’ve been a resident of the Pioneer Valley
my entire life. I graduated from the Hartford Art
School in 2012 with a BFA in illustration and
an art history minor. I’m an all-around creative
person. When I’m not working full time, I am a
freelance caricature artist, crafter, writer, and
photographer.
Since I do not come from a medical
background myself, it is my hope to help make
The Innovator accessible and easily understood
by the everyday reader – someone who might
not necessarily be a medical professional or
researcher. The medical world fascinates me and
I am eager to learn more about it every day.
I look forward to keeping you all in the loop
about the great research happening throughout
the Baystate Health system. If you have any story
ideas for The Innovator, please feel free to send
me an email at allison.litera@baystatehealth.org.
We would be happy to consider your ideas!
Until next time,

Allie

sick, they want options. They
don’t want to have to go to
Boston or Hartford for the care
they are looking for. If research
is available to people, they’re
willing to listen and make a
choice.”
Clinical research is central to
Baystate’s mission of demonstrating how medical advances
can and should be applied to
improve human health.
“We at Baystate have
recognized that to ensure our
continued involvement in such
activity we must change the way
we do business with industry
sponsors,” concludes Steingrub.
“It is the CTO’s firm belief that
clinical research in general, and

industry sponsored trials in particular; belong at our academic
medical center. To date, industry
reactions to our CTO services
have been enthusiastic.”
The CTO team looks forward
to partnering with clinicians,
scientists, staff, patients and
families to expand opportunities for clinical trials and thus
advance the state of caring at
Baystate Health.
FOR MORE INFORMATION:
If you are interested
in learning more or participating in a clinical trial
at Baystate, visit www.
baystatehealth.org/patients/
learn-about-clinical-trials.

Jennifer Pacheco, MPH,
CIM, CIP promoted to Chief
Research Compliance Officer
Jennifer Pacheco, MPH, CIM, CIP
was promoted to Director, Healthcare
Research Compliance and Chief
Research Compliance Officer for Baystate Health, effective October 2018.
Pacheco joined Baystate‘s Human
Research Protection Program (HRPP)
in 2006. Promoted to HRPP Director in
2013, she has guided the institution and
its research teams in meeting ethical
principles and regulatory requirements
for research. Under her leadership, our
HRPP implemented process improvements for our IRBs that have greatly
reduced administrative burden and
time-to-approval, and passed brilliantly
two rounds of accreditation from the
Association for the Accreditation of
Human Research Protection Programs
(AAHRPP).
Pacheco’s new role as Director of
Healthcare Research Compliance
and Chief Research Compliance
Officer gives her a platform to educate
people about research in public, in the
hospital, and for medical professionals. It also gives a clear, centralized
institutional voice to research compliance issues. In her new role leading
the research compliance program, Ms.
Pacheco will have matrixed reporting to the Chief Research Officer and
to the Chief Compliance & Privacy
Officer. She will continue to oversee
administration of the HRPP, and collaborate with relevant departments in
ensuring adherence to research billing
compliance and research conflict of
interest policies. Her goals are to make
the research regulatory personnel
approachable and available to field any

Jennifer Pacheco, MPH, CIM, CIP

questions or concerns; minimize risks
to research subjects, employees, and
the institution; advance new standards
of research practice; and improve
efficiency in review and monitoring
to lower the burdens associated with
healthcare research.
“When people think of research
compliance, they may get a little
intimidated,” she explains, “but we are
here to help. We want get you where
you need to be, and still get you where
you’re looking to go.”
If you have any questions about
research compliance or human
research protection at Baystate Health,
call (413) 794-3458 or email jennifer.
pacheco@baystatehealth.org.
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Research at Baystate Franklin Medical Center
As an academic health system, Baystate Health performs research at all of its hospitals as part of its focus on advancing
care. For example, research has been growing at Baystate Franklin Medical Center in Greenfield, MA. Here we highlight a
couple of the latest projects occurring there.
SPEECH PATHOLOGY
RESEARCH WITH AMANDA
BERNHARD, MA, CCC-SLP
Parkinson’s disease can
cause problems with speech
in up to 90% of patients who
have it. Amanda Bernhard, MA,
CCC-SLP, is leading research
at BFMC comparing the effects
of rehabilitation exercises vs.
a worn device to combat the
communication challenges
presented by Parkinson’s. The
program that Bernhard offers
at BFMC is called LSVT LOUD
(LSVT stands for “Lee Silverman
Voice Treatment”). Research
supporting the effectiveness of
this program dates back to the
late 1980s. The intensive treatment is used globally to help
patients with Parkinson’s disease regain normalcy to their
speech. The research project
is hosted at the University of
Massachusetts Amherst and is
headed up by Dr. Kelly Richardson. The funding is provided by
the National Institutes of Health
(NIH).
“LSVT LOUD teaches,
through various phonation
and speech exercises, how to
use a louder voice,” explains
Bernhard. “It improves respiratory strength, vocal volume
and quality, speech clarity, and
swallowing function.” Most of
Bernhard’s patients have many
“success moments” that they
share with her. One woman
told Bernhard that completing
the LSVT program “restored
her confidence” and that she
felt she was able to make her
voice heard again. Another felt
so empowered by the LSVT
program that she felt inspired
to create a singing group for
individuals with Parkinson’s
at a local exercise center. A
gentleman Bernhard is working
with at the moment said that
his daughter, upon hearing his
louder voice over the phone,
told him “you sound like you
did two or three years ago, your
old voice is back!”
The other treatment option
used in the research study is
a device called a SpeechVive;
a hearing aid-type apparatus

Amanda Bernhard, MA, CCC-SLP,
a speech-language pathologist at
Baystate Franklin Medical Center.

fitted to and worn by an individual, just like a hearing aid.
When the individual speaks,
the SpeechVive turns on and
projects a babbling noise into
the background. This sound
encourages the wearer to
speak louder. The SpeechVive
was developed and invented
within the past couple years by
Jessica Huber, PhD, of Purdue
University. According to purdue.
edu, “The SpeechVive capitalizes on the Lombard effect.
This is the reflex that causes
us to speak louder, clearer,
and slower in the presence of
background noise. All adults
demonstrate this response.
People with Parkinson’s disease have difficulty with speech
loudness, clarity, and rate. The
SpeechVive has the potential to
improve all three domains via
the Lombard effect.”
“It is a newer device with not
a lot of research yet to back up
its effectiveness, but that’s what
we’re hoping this study helps
discover,” informs Bernhard. “It
seems like it could be an excellent tool for the right patient.”
The study will follow 12
participants in each treatment
group, and documentation of
the level of each participant’s
vocal volume and respiratory
support will be measured to
see how effective each method
is and to compare the results of
the two groups.
“If I can help by contributing

to the research that assists this
population, I will be delighted. It
is such a joy working with these
individuals,” adds Bernhard.
“With Parkinson’s patients in
particular, so many of them
have amazing things to say and
unfortunately feel unheard most
of the time. Giving them a safe,
fun space to work on their conversation abilities is a great part
of my job. I love that the LSVT
program is so empowering.”
Ultimately, Bernhard is
excited to help her patients
express their true voices again.
For more information, contact
Amanda Bernhard, MA, CCCSLP at Amanda.Bernhard@
baystatehealth.org or (413)
773-2411.
RURAL NEW ENGLAND
HEALTH STUDY WITH PETER
FRIEDMANN, MD, MPH,
DFASAM, FACP, PRINCIPAL
INVESTIGATOR
Researchers at UMMS-Baystate are conducting a study
funded by the National Institute
on Drug Abuse (NIDA), Centers for Disease Control and
Prevention (CDC), Substance
Abuse Mental Health Services
Administration (SAMHSA) and
the Appalachian Regional Commission to better understand
the opioid epidemic and the
availability of health services
in rural communities in New
England.
“In New England’s rural
areas,” says Dr. Peter Friedmann, Principal Investigator,
“the epidemic of opioid use
disorder (OUD) and its related
sequelae of overdose, HIV,
hepatitis C virus (HCV), sexually
transmitted infections (STIs) and
other infectious comorbidities
present the most substantial
challenges to public health and
health care in decades.”
Baystate is one of only
eight institutions throughout
the U.S. that received funding to participate in what has
become the National Rural
Opioid Initiative. The research
team is based at BFMC but is
working in locations throughout
the Interstate 91 corridor from

Greenfield all the way up north
to the Canadian border.
“We are looking for people
who use painkillers or nonmedically inject any type of
drugs,” says Randall Hoskinson,
Project Director for the study.
Study participants complete
a survey that asks a broad
range of questions about the
individual’s experiences with
substance use, their ability
or – as is often the case – their
inability to access different
services, stigma, and their
social network. They are also
tested for HIV, Hepatitis C, and
syphilis using rapid tests. Blood
samples are collected from
those who test positive for viral
genetics analysis conducted
through Massachusetts General
Hospital and the CDC. The
UMMS-Baystate Research team
and partners at Dartmouth and
Tufts will use survey responses
and blood test results to map
opioid use and the spread of
infectious disease throughout
the region.
“This information will be
compared with what is available in terms of substance
use treatment, harm reduction (e.g. needle exchanges
and naloxone distribution),
health services, and infectious
disease specialty care,” adds
Hoskinson. The data collected
will help create a better, more
accessible system of care and
resources for persons with substance use disorders in order
to reduce overdose deaths
and the spread of infectious
diseases.
But first, the team must collect the data. To begin recruiting participants, study staff
goes out into the community
and talk to people walking
down the street, or stopping
into a gas station or convenience store.
“We start up a general
conversation,” explains Julie
Kingsbury, Clinical Research
Coordinator. “We target people
who we think might be eligible
for this study, or to see if they
may know someone who
(Continued on page 4)
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Lanspa MJ, Gong MN, Schoenfeld DA, Lee KT, Grissom
CK, Hou PC, Serpa-Neto A,
Brown SM, Iwashyna TJ, Yealy
DM, Hough CL, Brower RG,
Calfee CS, Hyzy RC, Matthay
MA, Miller RR 3rd, Steingrub
JS, Thompson BT, Miller CD,
Clemmer TP, Hendey GW,
Huang DT, Mathews KS, Qadir
N, Tidswell M. Prospective
Assessment of the Feasibility
of a Trial of Low Tidal Volume
Ventilation for Patients with
Acute Respiratory Failure. Ann
Am Thorac Soc. 2018 Nov 8.
Wu H, Huffman AM, Whitcomb

(Continued from page 3)
is.” Respondent Driven
Sampling (RDS) is utilized
for recruitment. RDS is a
referral-based system that
is used to find members
of hard-to-reach or hidden
populations. Participants
are given coupons to
distribute to other people
they know who use drugs
and are given an incentive
for successful referrals of
peers that take part in the
study.
“With this research, we
are learning from people
who know firsthand what
it’s like to use opioids and
inject drugs and live in a
rural area, something that
has been looked at very
little in the past,” adds Elyse
Bianchet, Research Assistant. Breaking the stigma
surrounding addiction is a
goal as well.
“People can be afraid to
admit that they use. They
may be afraid that we have
something to do with the
law. We stress that this is
100% confidential,” assures
Kingsbury. Along with confidentiality, what the team
values most is treating
participants with respect,

BW, Josyula S, Labrie S, Tougias E, Rahil T, Sites CK, Pilsner
JR. Sperm mitochondrial DNA
measures and semen parameters among men undergoing
fertility treatment. Reprod
Biomed Online. 2018 Nov 16.
Johnson KG, Johnson DC,
Thomas RJ, Feldmann E,
Lindenauer PK, Visintainer
P, Kryger MH. Flow limitation/
obstruction with recovery
breath (FLOW) event for
improved scoring of mild
obstructive sleep apnea without electroencephalography.
Sleep Med. 2018 Nov 30.

Leung B, Madhuripan N, Bittner
K, Rastegar V, Banever G,
Tashjian D, Moriarty K, Polansky S, Tirabassi M. Clinical
outcomes following identification of tip appendicitis on
ultrasonography and CT scan.
J Pediatr Surg. 2018 Oct 5.
Al-Azizi KM, Grewal V, Gobeil
K, Maqsood K, Haider A,
Mohani A, Giugliano G, Lotfi
AS. The left distal trans-radial
artery access for coronary
angiography and intervention:
A US experience. Cardiovasc
Revasc Med. 2018 Oct 25.

dignity, and compassion
without judgement.
“We reassure them that
their drug use doesn’t
define them, and we
always make it clear we
appreciate their time and
input and that their time
and input is extremely
valuable,” adds Bianchet.
“Many people who use
drugs do so because they
have experienced a lot
of trauma. Living in active
addiction is an ordeal in
itself. Someone injecting
heroin every day is not having fun. It’s a lonely, painful,
difficult place.” Thus, the
majority of participants are
enthusiastic that the study
is taking place because
they want to help make the
situation better for others
across New England.
“They know this is
important work, and they
are eager and proud to
be a part of it,” adds Eric
Romo, a MD-PhD student
at UMMS-Worcester who
is working with the team.
Even with the success
they have had recruiting,
almost 400 participants
since Memorial Day, there’s
still a bit of mystery to the

Krajewski D, Kaczenski E,
Rovatti J, Polukort S, Thompson C, Dollard C, Ser-Dolansky
J, Schneider SS, Kinney SRM,
Mathias CB. Epigenetic Regulation via Altered Histone Acetylation Results in Suppression
of Mast Cell Function and Mast
Cell-Mediated Food Allergic
Responses. Front Immunol.
2018 Oct 23;9:2414.
Anastasio HB, Campbell LE,
Buermeyer A, Saccone G,
Moreno S, Cruz Y, Berghella V,
Schoen C, Roman A. Nonsteroidal Antiinflammatory Drug
Administration and Postpartum

Blood Pressure in Women
With Hypertensive Disorders
of Pregnancy. Obstet Gynecol.
2018 Nov 5.
Spitzer KA, Stefan MS, Priya
A, Pack QR, Pekow PS, Lagu
T, Pinto-Plata VM, ZuWallack
RL, Lindenauer PK. Participation in Pulmonary Rehabilitation Following Hospitalization
for COPD among Medicare
Beneficiaries. Ann Am Thorac
Soc. 2018 Nov 12.

New Faces of Research
Vera Postell
Staff Assistant

Carolina Clark
Clinical Research
Assistant II
Julie Kingsbury, Clinical
Research Coordinator; Ely
Bianchet, Research Assistant;
and Eric Romo, MD-PhD student
at UMMS-Worcester, outside of
BFMC’s Research Offices.

community of drug users as
a whole.
“All in all, we will never
be sure of how many people use opioids,” concludes
Kingsbury. “There’s a whole
population that doesn’t
want to be known.”
For more information
on the Rural New England
Health Study, or to find out
how to participate, contact
Julie Kingsbury at Julie.
Kingsbury@baystatehealth.
org or (413) 773-4422.
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